Compare · GSK vs PFE
GSK vs PFE
Side-by-side comparison of GSK plc (GSK) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GSK and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $138.44B, about 1.3x GSK ($107.07B).
- Over the past year, GSK is up 36.1% and PFE is up 0.4% - GSK leads by 35.7 points.
- Both names hit the wire about 21 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- GSK plc
- Pfizer Inc.
- Price
- $52.49+1.18%
- $24.27+2.47%
- Market cap
- $107.07B
- $138.44B
- 1M return
- +1.76%
- -7.36%
- 1Y return
- +36.11%
- +0.37%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2022
- News (4w)
- 21
- 21
- Recent ratings
- 25
- 25
GSK plc
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest GSK
- SEC Form 6-K filed by GSK plc
- SEC Form 6-K filed by GSK plc
- SEC Form 6-K filed by GSK plc
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- SEC Form 6-K filed by GSK plc
- SEC Form 6-K filed by GSK plc
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- SEC Form 11-K filed by GSK plc
- SEC Form 11-K filed by GSK plc
Latest PFE
- Pfizer Declares Third-Quarter 2026 Dividend
- FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
- Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Pfizer Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Pfizer Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Pfizer Announces Chief Financial Officer Transition
- SEC Form 4 filed by Chairman & CEO Bourla Albert
- SEC Form 11-K filed by Pfizer Inc.